Table 1 Baseline demographics and clinical characteristics of patients^a

Number of patients

29

Age (years), median (IQR)

39.0 (35.5–44.0)

Gender, male, n (%)

26 (89.7)

BMI (kg/m²), median (IQR)

20.2 (18.7–23.6)

Current smoking, n (%)

12 (41.4)

Prior AIDS diagnosis, n (%)

10 (34.5)

Time since diagnosis HIV (years), median (IQR)

4 (1–9)

HIV-RNA < 50 copies/mL, n (%)

29 (100)

CD4 cell count (cells/µL), median (IQR)

438 (301–805)

Time on antiretroviral therapy (years), median (IQR)

4 (1–8)

Backbone drug

 TAF/FTC, n (%)

13 (44.8)

 TDF/FTC, n (%)

10 (34.5)

 ABC/3TC, n (%)

6 (20.7)

Key drug class

 INSTI, n (%)

18 (62.1)

 PI, n (%)

10 (34.5)

 NNRTI, n (%)

1 (3.4)

 Number of non-HIV medications, median (IQR)

2 (1–4)

 Use of ≥ 5 non-HIV medications, n (%)

1 (3.4)

 Serum-corrected Ca (mg/dL), median (IQR)

9.2 (9.0–9.4)

 BP pre-treatment, n (%)

6 (20.7)

 Lumbar spine BMD (g/cm²), median (IQR)

0.798 (0.753–0.873)

 Femoral neck BMD (g/cm²), median (IQR)

0.606 (0.570–0.660)